Treats osteoporosis in postmenopausal women. Sold as Fosamax Plus D. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Alendronate Sodium; Cholecalciferol (sold as Fosamax Plus D), first approved Apr 7, 2005, with 1 new use approved and 0 published complete response letters.
| Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)Osteoporosis, Postmenopausal · 424 General Military Hospital | — | Active, not recruiting | Oct 12, 2022 |
| Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone TurnoverAge-Related Osteoporosis · Madhumathi Rao | Phase 4 | Active, not recruiting | Dec 9, 2021 |
| Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary OsteoporosisBeta Blocker Toxicity · Sherief Abd-Elsalam | Phase 3 | Recruiting | Jan 12, 2021 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 7, 2005 | Fosamax Plus DNDA 21762 · New combination | Organon LLC | 17 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA